FDA RF microneedling safety communication: key facts

On October 15, 2025, the U.S. Food and Drug Administration issued a safety communication about serious complications reported with certain uses of radiofrequency microneedling. The reports included burns, scarring, fat loss, disfigurement, and nerve damage; the agency noted that serious outcomes may require intervention [1].

The communication did not ban the procedure, establish how often each complication occurs, or state that every RF microneedling treatment is unsafe. It said the FDA's evaluation was ongoing and asked patients and health professionals to report complications [1]. That distinction matters: a postmarket safety signal deserves attention without inventing an incidence rate or a causal conclusion the agency has not published.

What changed in October 2025?

The FDA had already published general information about microneedling devices, authorized uses, and known risks [2]. The 2025 communication added a focused warning about serious complications reported after certain dermatologic and aesthetic uses of devices that combine needles with radiofrequency energy [1].

The agency described RF microneedling as a medical procedure, not merely a cosmetic service. It recommended that patients seek a licensed health care provider trained in the procedure and that providers use FDA-authorized devices for their authorized uses [1]. The FDA also said RF microneedling devices should not be used at home.

The exact language “certain uses” is important. The communication did not identify one universal risk across every device, depth, energy setting, body site, and operator. It also did not provide a denominator, so the number of procedures performed without a reported serious event is unknown from the notice alone.

RF microneedling and regular microneedling are different

Standard microneedling creates controlled mechanical punctures. RF microneedling adds radiofrequency energy through the needles, producing heat in or below the skin [1][2]. Needle insulation, depth, pulse duration, energy, contact, number of passes, and tissue anatomy can affect where that heat is deposited.

Grouping both procedures under one name can hide a clinically important difference. Evidence about mechanical microneedling cannot prove the safety of an RF device at a particular energy and depth.

What was reported, and what remains unknown?

The FDA listed serious reported outcomes but did not release a case count, incidence rate, device-by-device analysis, or final causal assessment in the communication [1]. It is therefore accurate to say that the agency received or was aware of reports. It is not accurate to calculate a risk percentage from the notice.

Postmarket reports can identify rare or unexpected patterns that a clinical trial is too small to detect. They also have limitations. Reports may omit settings, technique, medical history, follow-up, or confirmation. More severe outcomes are more likely to be reported than mild ones, and the number of exposed patients may be unknown.

Those limitations do not justify ignoring the signal. They explain why the FDA requested additional reporting and why device, indication, technique, and operator training need to stay attached to any safety claim [1].

How does this fit with the earlier literature?

A 2021 systematic review of 85 microneedling publications found that most reported adverse effects were transient, such as redness, swelling, pain, dryness, and exfoliation. It also identified persistent post-inflammatory hyperpigmentation, tram-track scarring, and granulomatous reactions [3]. The review included different microneedling techniques and literature available through 2019, before the FDA's 2025 RF-specific alert.

Another systematic review of nine randomized trials found no serious adverse effects in the included studies of microneedling for atrophic scars [4]. That result applies to those trials and sample sizes. It cannot rule out rare events or override later postmarket reports involving different RF devices or uses.

This is a common evidence pattern in device safety:

1. Controlled trials estimate common outcomes in selected participants.
2. Broader clinical use introduces more operators, devices, settings, and anatomies.
3. Postmarket reporting can reveal serious events that were absent from small trials.
4. Regulators investigate whether the reports indicate a causal device or use pattern.

Our earlier RF microneedling evidence review summarizes efficacy studies. The FDA communication adds newer safety context and should be read alongside, not replaced by, efficacy evidence.

Questions to ask before a procedure

The FDA recommends selecting a licensed provider trained in RF microneedling and asking whether the device is FDA authorized for the proposed use [1][2]. Useful factual questions include:

• What is the exact manufacturer and model?
• Is the proposed body area and use within the device's clearance?
• Who will perform the procedure, and what training do they have on this device?
• Will a new cartridge be used for this session?
• What depth and energy range is planned, and why is it appropriate for this anatomy?
• How are pigment change, infection, burns, fat loss, and nerve injury recognized and managed?
• Which symptoms require urgent contact or in-person assessment?

An FDA 510(k) clearance is device and indication specific. It is not a blanket endorsement of every setting, technique, combination product, or off-label body area.

When should a complication be assessed?

Expected short-term effects can include redness, swelling, pinpoint bleeding, tenderness, dryness, or crusting [2][3]. The FDA communication raises concern about more serious or persistent findings after RF treatment [1].

Prompt assessment is appropriate for blistering, escalating pain, spreading discoloration, weakness or numbness, a new contour depression, signs of infection, an open wound, visual symptoms, or changes that worsen instead of settling. Emergency symptoms need urgent medical care rather than a social-media diagnosis.

Patients and clinicians can report suspected device problems through FDA MedWatch [1]. A report does not by itself prove causation, but reporting helps regulators identify patterns.

Bottom line

The FDA's October 2025 communication is a safety signal about serious complications reported with certain RF microneedling uses [1]. It does not provide a complication rate, ban the procedure, or show that every device carries identical risk.

The practical conclusions are narrower and stronger: RF microneedling is a medical procedure, it differs from mechanical microneedling, it should not be performed at home, and the exact device, authorized use, settings, anatomy, and operator training matter [1][2]. Earlier trials with few serious events cannot exclude rare harms reported later in broader use [3][4].

This article is for informational purposes and does not constitute medical advice. Questions about a planned procedure or a possible complication should be directed to a qualified clinician.